Role of zinc supplemenation on height of thalassemia patients.

Role of oral zinc supplementation on linear growth in transfusion dependent thalassemia patients

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/052086

Enrollment

Registered

2023-04-28

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D758- Other specified diseases of bloodand blood-forming organs Health Condition 2: D758- Other specified diseases of bloodand blood-forming organs

Interventions

Intervention1: Zinc sulphate tablets: GROUP A WILL BE GIVEN ORAL ZINC SULPHATE AND ITS ROLE ON LINEAR GROWTH WILL BE SEEN FOR A YEAR Intervention2: Oral zinc sulphate Tablets: Group 1 will be given or

Eligibility

Inclusion criteria

Inclusion criteria: 1)Transfusion dependent thalassemia Patients in age group (1-10years) 2)Height <50th centile as per WHO and IAP combined growth charts

Exclusion criteria

Exclusion criteria: 1)Height >50th centile 2)Thalassemia patients who are known case of chronic disorders affecting growth (CKD/CLD/hypersplenism/hypothyroidism)

Design outcomes

Primary

Measure	Time frame
Role of oral zinc suuplementation on linear growth in thalassemia patientsTimepoint: 12 months	—

Secondary

Measure	Time frame
To study the adverse effects of zinc in zinc supplemented groupTimepoint: 12 months	—

Countries

India

Contacts

Public ContactDr Akash Jaiswal

Motilal Nehru Medical College

mukeshvirsingh@gmail.com9456630304

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026